Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan ...

As treatment for spinal muscular atrophy (SMA) has drastically improved over the last decade, so too have survival rates and the number of people with SMA living well into adulthood. | A new education ...

Investors in Novartis (Symbol: NVS) saw new options become available today, for the August 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVS options ...

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto® (lutetium (177Lu) vipivotide tetraxetan injection) is publicly reimbursed in Quebec for ...

Switzerland’s medical products authority has granted the first approval for a malaria medicine designed for small infants, ...

A new treatment for malaria in babies and very small children has just been approved; we hear more about the drug expected to save many lives.

Novartis said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...

Novartis AG Annual cash flow by MarketWatch. View NOVN net cash flow, operating cash flow, operating expenses and cash dividends.

Bhartiya Vidya Bhavan's S.P. Jain Institute of Management and Research (SPJIMR) welcomed the incoming cohort of its flagship ...

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), ...